AU2012306386B2 - Polymorphic form of pridopidine hydrochloride - Google Patents
Polymorphic form of pridopidine hydrochloride Download PDFInfo
- Publication number
- AU2012306386B2 AU2012306386B2 AU2012306386A AU2012306386A AU2012306386B2 AU 2012306386 B2 AU2012306386 B2 AU 2012306386B2 AU 2012306386 A AU2012306386 A AU 2012306386A AU 2012306386 A AU2012306386 A AU 2012306386A AU 2012306386 B2 AU2012306386 B2 AU 2012306386B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- propyl
- methanesulfonyl
- hydrochloride salt
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- YGRHOYQMBLLGEV-UHFFFAOYSA-N 4-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride Chemical compound Cl.C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGRHOYQMBLLGEV-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 36
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229960003638 dopamine Drugs 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229950003764 pridopidine Drugs 0.000 abstract description 12
- 238000011161 development Methods 0.000 abstract description 6
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 5
- 229940088679 drug related substance Drugs 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000013078 crystal Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 10
- 230000008018 melting Effects 0.000 description 10
- 238000002411 thermogravimetry Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000001757 thermogravimetry curve Methods 0.000 description 5
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000005102 attenuated total reflection Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012296 anti-solvent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000007416 differential thermogravimetric analysis Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170496 | 2011-09-07 | ||
| DKPA201170496 | 2011-09-07 | ||
| US201161533550P | 2011-09-12 | 2011-09-12 | |
| US61/533,550 | 2011-09-12 | ||
| PCT/EP2012/067371 WO2013034622A1 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012306386A1 AU2012306386A1 (en) | 2014-04-17 |
| AU2012306386B2 true AU2012306386B2 (en) | 2017-06-15 |
Family
ID=47831564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012306386A Ceased AU2012306386B2 (en) | 2011-09-07 | 2012-09-06 | Polymorphic form of pridopidine hydrochloride |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9006445B2 (enExample) |
| EP (1) | EP2753603B1 (enExample) |
| JP (2) | JP6189299B2 (enExample) |
| KR (1) | KR20140075703A (enExample) |
| CN (1) | CN103958469B (enExample) |
| AU (1) | AU2012306386B2 (enExample) |
| BR (1) | BR112014005389A8 (enExample) |
| CA (1) | CA2847736A1 (enExample) |
| EA (1) | EA023462B1 (enExample) |
| ES (1) | ES2639052T3 (enExample) |
| IL (1) | IL231149A0 (enExample) |
| MX (1) | MX343620B (enExample) |
| WO (1) | WO2013034622A1 (enExample) |
| ZA (1) | ZA201402492B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| SG10201506761XA (en) | 2010-09-03 | 2015-10-29 | Teva Pharmaceuticals Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| MX384234B (es) * | 2013-06-21 | 2025-03-14 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para el tratamiento de enfermedad de huntington. |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| EP4282479A3 (en) | 2015-02-25 | 2024-02-21 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat depression or anxiety |
| AR105434A1 (es) * | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| US11738012B2 (en) | 2016-02-24 | 2023-08-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| DK3503890T3 (da) | 2016-08-24 | 2025-01-27 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af dystonier |
| BR112019003732A2 (pt) | 2016-08-24 | 2020-02-18 | Prilenia Therapeutics Development Ltd. | Aplicação de pridopidina para tratamento de declínio funcional |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| JP7114604B2 (ja) | 2017-01-20 | 2022-08-08 | プリレニア ニューロセラピューティクス リミテッド | 脆弱ｘ症候群の治療のためのプリドピジンの使用 |
| EP3357909A1 (en) | 2017-02-02 | 2018-08-08 | Sandoz AG | Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine |
| DK3668509T3 (da) | 2017-08-14 | 2023-02-20 | Prilenia Neurotherapeutics Ltd | Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin |
| MX2020002310A (es) | 2017-08-30 | 2020-09-17 | Prilenia Neurotherapeutics Ltd | Formas de dosificacion de alta concentracion de pridopidina. |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN111343982A (zh) * | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
| JP7585561B2 (ja) | 2019-02-04 | 2024-11-19 | プリレニア ニューロセラピューティクス リミテッド | パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2006040155A1 (en) * | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| GB0329236D0 (en) * | 2003-12-17 | 2004-01-21 | Arakis Ltd | Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride |
| EP2204363A1 (en) | 2004-06-08 | 2010-07-07 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
| PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| CN101765428A (zh) | 2007-06-18 | 2010-06-30 | A·卡尔森研究股份有限公司 | 多巴胺稳定剂的用途 |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| SG10201506761XA (en) | 2010-09-03 | 2015-10-29 | Teva Pharmaceuticals Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| IN2015DN03219A (enExample) | 2012-09-27 | 2015-10-02 | Teva Pharma | |
| HK1211483A1 (en) | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease |
-
2012
- 2012-09-06 CA CA 2847736 patent/CA2847736A1/en not_active Abandoned
- 2012-09-06 KR KR20147009105A patent/KR20140075703A/ko not_active Ceased
- 2012-09-06 BR BR112014005389A patent/BR112014005389A8/pt not_active IP Right Cessation
- 2012-09-06 EP EP12755869.0A patent/EP2753603B1/en active Active
- 2012-09-06 WO PCT/EP2012/067371 patent/WO2013034622A1/en not_active Ceased
- 2012-09-06 AU AU2012306386A patent/AU2012306386B2/en not_active Ceased
- 2012-09-06 ES ES12755869.0T patent/ES2639052T3/es active Active
- 2012-09-06 MX MX2014002731A patent/MX343620B/es active IP Right Grant
- 2012-09-06 EA EA201490569A patent/EA023462B1/ru not_active IP Right Cessation
- 2012-09-06 US US14/342,253 patent/US9006445B2/en active Active
- 2012-09-06 CN CN201280043794.9A patent/CN103958469B/zh active Active
- 2012-09-06 JP JP2014528965A patent/JP6189299B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-25 IL IL231149A patent/IL231149A0/en unknown
- 2014-04-04 ZA ZA2014/02492A patent/ZA201402492B/en unknown
-
2017
- 2017-05-31 JP JP2017107986A patent/JP2017206516A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046145A1 (en) * | 1999-12-22 | 2001-06-28 | A. Carlsson Research Ab | New modulators of dopamine neurotransmission |
| WO2006040155A1 (en) * | 2004-10-13 | 2006-04-20 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1199728A1 (en) | 2015-07-17 |
| US20140315951A1 (en) | 2014-10-23 |
| EP2753603B1 (en) | 2017-06-21 |
| NZ623344A (en) | 2015-10-30 |
| JP2014525470A (ja) | 2014-09-29 |
| EA201490569A1 (ru) | 2014-09-30 |
| JP6189299B2 (ja) | 2017-08-30 |
| CA2847736A1 (en) | 2013-03-14 |
| KR20140075703A (ko) | 2014-06-19 |
| IL231149A0 (en) | 2014-04-30 |
| AU2012306386A1 (en) | 2014-04-17 |
| US9006445B2 (en) | 2015-04-14 |
| ZA201402492B (en) | 2015-07-29 |
| EP2753603A1 (en) | 2014-07-16 |
| CN103958469A (zh) | 2014-07-30 |
| MX343620B (es) | 2016-11-11 |
| EA023462B1 (ru) | 2016-06-30 |
| BR112014005389A2 (pt) | 2017-03-28 |
| MX2014002731A (es) | 2014-04-30 |
| CN103958469B (zh) | 2016-04-20 |
| BR112014005389A8 (pt) | 2018-04-03 |
| JP2017206516A (ja) | 2017-11-24 |
| WO2013034622A1 (en) | 2013-03-14 |
| ES2639052T3 (es) | 2017-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012306386B2 (en) | Polymorphic form of pridopidine hydrochloride | |
| US9814706B2 (en) | Hydrobromide salt of pridopidine | |
| JP7244575B2 (ja) | 結晶性化合物 | |
| JP2018517742A5 (enExample) | ||
| JP5968881B2 (ja) | カルシウム模倣化合物の新規多形 | |
| US11208382B2 (en) | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof | |
| US10513500B2 (en) | Crystalline forms of Lesinurad | |
| HK1199728B (en) | Polymorphic form of pridopidine hydrochloride | |
| NZ623344B2 (en) | Polymorphic form of pridopidine hydrochloride | |
| JP5968880B2 (ja) | カルシウム模倣化合物の新規多形 | |
| WO2017196859A1 (en) | A novel polymorph of itraconazole with improved pharmaceutical properties | |
| RU2789672C2 (ru) | Кристаллические соединения | |
| KR20230155499A (ko) | 다중-티로신 키나제 억제제의 결정질 염, 제조 방법, 및 이의 용도 | |
| EP4114835A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |